The University of Barcelona and Bruker have partnered to advance pharmaceutical research through the use of 1 GHz NMR technology. This collaboration aims to enhance the characterization of therapeutic monoclonal antibodies and oligonucleotides by leveraging cutting-edge NMR techniques and high-field instrumentation.
The companies NovAliX, Alysophil, De Dietrich Process Systems and Bruker have joined forces to bring to market a new approach to active pharmaceutical ingredient (API) production. The partnership will leverage its complementary skills to provide a complete, standalone, and location-independent API manufacturing solution to a pharmaceutical company or contract manufacturing organization.
We interviewed each of the partners to learn more about this innovative project.